Detalhe da pesquisa
1.
Sustained remission induced by 2 years of treatment with benralizumab in patients with severe eosinophilic asthma and nasal polyposis.
Respirology
; 2024 Jun 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-38847185
2.
Omalizumab in middle-aged or older patients with severe allergic asthma-COPD overlap.
Postepy Dermatol Alergol
; 39(1): 88-93, 2022 Feb.
Artigo
em Inglês
| MEDLINE | ID: mdl-35369622
3.
Tropomyosin: A panallergen that causes a worldwide allergic problem.
Allergy Asthma Proc
; 42(5): e145-e151, 2021 Sep 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-34474717
4.
Hymenoptera sting reactions in southern Italy forestry workers: our experience compared to reported data.
Clin Mol Allergy
; 16: 8, 2018.
Artigo
em Inglês
| MEDLINE | ID: mdl-29686538
5.
Benralizumab in Patients with Severe Eosinophilic Asthma: A Multicentre Real-Life Experience.
J Clin Med
; 12(13)2023 Jun 28.
Artigo
em Inglês
| MEDLINE | ID: mdl-37445397
6.
Effectiveness and safety of anti-IL-5/Rα biologics in eosinophilic granulomatosis with polyangiitis: a two-year multicenter observational study.
Front Immunol
; 14: 1204444, 2023.
Artigo
em Inglês
| MEDLINE | ID: mdl-37457743
7.
Real-world characteristics of "super-responders" to mepolizumab and benralizumab in severe eosinophilic asthma and eosinophilic granulomatosis with polyangiitis.
ERJ Open Res
; 9(5)2023 Sep.
Artigo
em Inglês
| MEDLINE | ID: mdl-37908397
8.
Real-life effects of dupilumab in patients with severe type 2 asthma, according to atopic trait and presence of chronic rhinosinusitis with nasal polyps.
Front Immunol
; 14: 1121237, 2023.
Artigo
em Inglês
| MEDLINE | ID: mdl-37063895
9.
Exploring Machine Learning Techniques to Predict the Response to Omalizumab in Chronic Spontaneous Urticaria.
Diagnostics (Basel)
; 11(11)2021 Nov 20.
Artigo
em Inglês
| MEDLINE | ID: mdl-34829497